Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg. In this regard, the company has enclosed a press release today.
The above information is a part of company’s filings submitted to BSE.